Cardiovascular effects of immunosuppression agents

Abstract

Immunosuppressive medications are widely used to treat patients with neoplasms, autoimmune conditions and solid organ transplants. Key drug classes, namely calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and purine synthesis inhibitors, have direct effects on the structure and function of the heart and vascular system. In the heart, immunosuppressive agents modulate cardiac hypertrophy, mitochondrial function, and arrhythmia risk, while in vasculature, they influence vessel remodeling, circulating lipids, and blood pressure. The aim of this review is to present the preclinical and clinical literature examining the cardiovascular effects of immunosuppressive agents, with a specific focus on cyclosporine, tacrolimus, sirolimus, everolimus, mycophenolate, and azathioprine.

Introduction

Medications that target and downregulate the immune system are utilized for the prevention and treatment of a variety of conditions, including neoplasms, autoimmune diseases, and acute rejection after solid organ transplantation (1). In a recent cohort, 2.8% of the adult population was treated with long-term immunosuppressive medications, consistent with prior self-reported estimates (2, 3). In addition to the well described increased risk of infection and malignancy in chronically immunosuppressed patients, many of these agents exhibit direct effects on the cardiovascular system including risk of left ventricular (LV) hypertrophy, myocardial fibrosis, arrhythmia, hypertension, dyslipidemia, and coronary atherosclerosis (4). Herein, we focus on the cardiovascular effects and mechanistic underpinnings of calcineurin inhibitors (CNI), mammalian target of rapamycin (mTOR) inhibitors, and purine synthesis inhibitors (Figure 1).

Figure 1

Hypertrophy and fibrosis

Cardiac hypertrophy is a feature of adverse cardiac remodeling that may be driven by genetic or acquired factors. Hypertrophy is frequently seen in association with diastolic dysfunction and represents an important marker for adverse remodeling (5, 6). Much of the focus on immunosuppression-induced cardiac remodeling has been on the effects on cardiac hypertrophy in native or transplanted hearts (7–9) (Table 1).

Calcineurin inhibitors

Calcineurin, a calcium and calmodulin-dependent phosphatase, plays a pivotal role in cardiac hypertrophy by translocating to the nucleus and dephosphorylating NFAT, allowing it to transcribe genes to activate hypertrophy in cardiomyocytes. Cyclosporine (CsA) binds to cyclophilin A, forming a complex with high affinity for calcineurin, which in turn inhibits its nuclear translocation. This is hypothesized to inhibit activation of NFAT-mediated hypertrophy (59). Tacrolimus binds to FK506-binding protein (FKBP12) to inhibit calcineurin activity driving reduced NFAT-mediated transcription of hypertrophic genes.

In early animal experiments, CsA successfully prevented or attenuated cardiac hypertrophy in mice overexpressing contractile elements (10, 29), genetic predispositions to hypertrophy (19), and treatment with exogenous chemical signals promoting hypertrophy (11, 15, 60). However, these data were challenged by the failure of CsA to prevent hypertrophy in several models of hypertension or pressure overload (16, 35, 61). Tacrolimus has also yielded mixed results. In murine models of genetic hypertrophic cardiomyopathy, tacrolimus exacerbated cardiac hypertrophy (37). In animal models of hypertrophy induced by phenylephrine stimulation, spontaneously hypertensive rats, or aortic banding, tacrolimus treatment had variable effects, with exacerbation or amelioration of the hypertrophic phenotype (16, 38, 61, 62).

Some hypothesized that the mixed results were driven by variability in hypertrophic signaling from genetic/sarcomeric-driven hypertrophic signaling vs. adaptive chemical or afterload-driven hypertrophy (37, 59). This hypothesis is somewhat weakened by mixed data for transverse aortic constriction rodent models.

Subsequent investigations suggested that CsA-induced effects on hypertrophic remodeling may be driven by increased fibrosis. Multiple studies have shown that CsA treatment led to increases in MMP2, MMP9, and Collagen I in dose dependent manner (20–22, 63). Rat hearts treated with CsA exhibited increased fibrosis/collagen content (64). Similar data of increased collagen deposition in response to tacrolimus treatment was observed in human induced pluripotent stem cell-derived cardiac organoids treated with tacrolimus (65). The in vitro findings suggest that increased fibrosis is not a result of calcineurin-induced hypertension.

Notwithstanding some of the conflicting data in animal models, the data from humans have been fairly consistent as to the effects of CsA and tacrolimus on human hearts. Endomyocardial biopsies from heart or liver transplant patients treated with CsA showed structural distortion, increased fibrosis, and increased collagen levels (25, 26). Furthermore, patients treated with CsA and tacrolimus had hypertrophy or increased LV mass on autopsy or imaging (8, 26, 27, 39, 40). A clinical trial investigating the effect of CsA in patients with hypertrophic cardiomyopathy was initiated, but it is unclear if the study was completed and findings, if any, were not published (66).

Despite some earlier reports of amelioration of cardiac hypertrophy by CNI, there is no clear evidence in humans to corroborate this finding. Supported by in vitro and human data, a consistent signal of increased hypertrophy and fibrosis associated with CNI treatment is observed (23, 28). Cellular data highlight that the increase in LV mass may be driven primarily by CNI-induced increase in fibrosis and collagen deposition rather than cardiomyocyte remodeling.

mTOR inhibitors

mTOR inhibitors, such as sirolimus and everolimus, inhibit mammalian target of rapamycin complex I, thereby inhibiting downstream pathways driving cell growth, proliferation, and survival. There are notable differences between sirolimus and everolimus (67). Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus, and differs in its subcellular distribution, pharmacokinetics and binding affinity. Compared to sirolimus, everolimus has higher bioavailability and shorter half-life. Both drugs form a complex with FKBP-12, which binds mTOR. However, everolimus binding to FKBP-12 is ~3-fold weaker than that of sirolimus, leading to significant differences in inhibition of mTORC2 activation and downstream effects (68, 69). Clinically this has translated into differences in side effect profile and potency of each drug.

This class of drugs has garnered significant interest in solid organ transplantation owing to salutary effects on renal function, allograft vasculopathy and malignancy risk (70). Sirolimus has been shown to reduce cardiac hypertrophy and fibrosis in animal models of pressure overload, uremia, and adriamycin induced cardiomyopathy (42, 43, 71). In a rat model of myocardial infarction, everolimus improved post-infarct remodeling (72) although in the recently published CLEVER-ACS trial of patients with myocardial infarction, there everolimus treatment had no effect on myocardial remodeling (73). Cellular data suggest that attenuation of adverse cardiac remodeling by mTOR inhibitors may be related in part to reduced cardiac fibroblast proliferation and collagen secretion (65).

The favorable signal for sirolimus has been validated in human studies, which largely compared outcomes to subjects treated with CNI. Sirolimus has been associated with improvement in diastolic dysfunction and filling pressures, possibly through attenuation of fibrosis (47–49). In patients with heart transplantation, everolimus treatment was associated with less myocardial fibrosis than mycophenolate treatment by biopsy and imaging (50, 51). The data in kidney transplant patients has been more mixed with some suggesting less LV hypertrophy with the use of everolimus (74), while a number of randomized trials showed no difference in LV mass index after conversion from CsA to everolimus post-kidney transplant (52–55). The incidence of adverse cardiovascular events from these studies was mixed with the majority showing no differences in outcomes (75–77). This discordant signal may be related to the fact that kidney transplant recipients often have concomitant hypertension and activation of the renin-angiotensin system that may have already contributed to significant adverse cardiac remodeling prior to kidney transplant—making it less likely to observe differences following kidney transplantation (75, 78). Additionally, most of the studies may have been underpowered to detect differences in cardiovascular outcomes.

Purine synthesis inhibitors

Purine synthesis inhibitors block cell proliferation by preventing the synthesis of DNA and RNA during S phase of the cell-cycle. Mycophenolate mofetil (MMF) treatment has been shown to prevent or attenuate ischemic injury and autoimmune myocarditis in animal models, with reduced secretion of inflammatory markers such as TLR4, NFκB, BAX expression, and TNFα (57, 58). There are no human studies suggesting a link between cardiac hypertrophy or fibrosis in association with MMF or azathioprine use.

Mitochondrial dysfunction

Mitochondria constitute a third of cardiomyocyte volume, and the heart, as a metabolically active organ, relies heavily on mitochondrial ATP production (79). Mitochondrial dysfunction is a feature of multiple types of cardiomyopathy, as it confers oxidative stress and changes in energetics to drive adverse cardiac remodeling. Immunosuppressive agents can exert direct effects on mitochondrial health to modulate cardiac remodeling and this has been subject of much investigation (Table 2).

Calcineurin inhibitors

Cyclophilin D is a protein in the inner mitochondrial matrix involved in opening of the mitochondrial permeability transition pore (mPTP) (94). mPTP opening results in mitochondrial calcium overload, release of cytochrome C, a process involved in apoptosis and implicated in myocardial ischemia-reperfusion (IR) injury (80). CsA interacts with cyclophilin D thereby preventing mPTP opening and protecting the mitochondria from calcium overload. Tacrolimus does not bind cyclophilin D and the effects of tacrolimus on mitochondrial function and mPTP opening are less defined. Multiple animal studies have sought to define the effect of both drugs on mitochondrial function.

CsA prevented mitochondrial-mediated injury and improved myocardial recovery in models of hypothermia, IR injury, and inborn errors of mitochondrial DNA polymerase (81–86, 95). In addition, CsA and/or tacrolimus have been associated with a favorable mitochondrial phenotype in the face of adriamycin treatment, hypoxia or endotoxemia (88–90).

Clinical data on the implications of these findings have been scant. In a single study of patients presenting with ST elevation myocardial infarction, CsA treatment decreased myocardial scar burden, which in combination with pre-clinical evidence provided promise for CsA as a “post-conditioning agent” during myocardial infarction (24, 30). However, follow-up studies failed to show any benefit to CsA treatment in regards to LV function, arrhythmia, or mortality (31–34). The discordance suggests that CsA protection from mitochondrial injury is largely a short term or acute benefit. No human studies to date have evaluated the effect of CNI on mitochondrial structure and function in light of associated cardiac remodeling.

mTOR inhibitors

Sirolimus has been associated with a reduction in respiration and cellular energetics in cardiomyocytes (92). This effect has been attributed to the observation that mTOR may activate AMP-activated protein kinase to regulate cellular bioenergetics (96). In a mouse model of cardiac IR injury, sirolimus inhibited apoptosis and improved cardiac performance via interaction with the mitochondrial ATP-sensitive potassium channel (93) and appears to reduce ER stress and cytochrome C release (97). In brain, sirolimus enhances the distribution of CsA into mitochondria, accentuating its effects of decreasing mitochondrial metabolism, whereas everolimus appears to antagonize the effects of CsA in mitochondria to increase energy metabolism (67, 98). At therapeutically relevant concentrations, everolimus, but not sirolimus, distributes into brain mitochondria (99, 100). As cited above clinical studies have suggested a favorable effect for mTOR inhibitors on cardiac remodeling—but data examining mitochondrial function is lacking.

Purine synthesis inhibitors

There are no reports of direct effects of MMF and Azathioprine on mitochondrial function in cardiomyocytes or heart tissue.

Arrhythmia

With described effects on myocardial structural remodeling and intracellular ion transporter function, immunosuppressive therapies may modulate the risk of arrhythmia. This poses significant short- and long-term risks, especially in patients with underlying structural heart disease and heart transplant recipients (Table 3).

Calcineurin inhibitors

Calcineurin affects intracellular calcium transients in cardiomyocytes via modulation of the ryanodine receptor and activation of the NFAT pathway, which drives transcriptional changes in proteins regulating intracellular calcium (124). Calcineurin inhibitors in turn can play a role in mediating changes in calcium transients impacting the electrical phenotype of the heart.

Delineating the precise effect of CNI on calcium regulation in human cardiomyocytes has proven elusive. In some models CsA appeared to reduce sarcoplasmic reticulum (SR) calcium release and cytosolic levels of Ca²⁺ (106). However, other models showed that both CsA and tacrolimus result in increased Ca²⁺ release events and an increase in QT prolongation. A possible mechanism of QT prolongation may be an increase in the duration of Ca²⁺ transients due to blockade of Na²⁺/Ca²⁺ exchanger. It is possible that CsA and tacrolimus exert different electrical phenotypes owing to their differential role in mitochondrial Ca²⁺ regulation and mPTP opening. Nonetheless the results in animal models of both drugs have been equally mixed; in some animal models, the cellular phenotypes of CNI appeared to translate to a reduced propensity to arrhythmia (103, 105, 106), but not in other models (101, 102).

Clinically, in case reports, CsA and tacrolimus induced atrial fibrillation and tacrolimus induced QT prolongation and atrial arrhythmias (107, 116). However, neither signal was seen in clinical trials with either drug suggesting that the arrhythmic risk is low (125, 126).

mTOR inhibitors

There are no published reports of mTOR inhibitors modulating risk of arrhythmias. The recently published CLEVER-ACS trial showed no difference in atrial arrhythmias in patients treated with everolimus after myocardial infarction (73).

Purine synthesis inhibitors

Azathioprine use is associated with increased incidence of atrial arrhythmias. In a 3-year randomized controlled trial of azathioprine vs. MMF, heart transplant patients treated with azathioprine had a higher rate of atrial arrhythmias than those on MMF (119). The mechanism for this phenomenon is unknown. There are no published reports of MMF modulating arrhythmia risk.

Hypertension

Hypertension is a well described side effect of immunosuppressive medication use, particularly CNI, and is associated with increased risk of coronary artery disease, cerebrovascular events, renal dysfunction, and adverse cardiovascular remodeling (Table 4).

Calcineurin inhibitors

CNI are known to cause hypertension, with 50–80% of patients reported to have hypertension with chronic use. CsA is associated with a higher incidence compared to tacrolimus (130). CNI are implicated in afferent arteriole vasoconstriction and activation of the renin-angiotensin system, promoting sodium retention and volume expansion (127, 149). Furthermore, CsA and tacrolimus are associated with promoting direct vasoconstriction by one or more of the following mechanisms: increased tone of vascular smooth muscle (128, 150, 151), reduced nitric oxide production (129), and activation of endothelin-1 receptor (129). In cultured murine endothelial and vascular smooth muscle cells, both CsA and tacrolimus were associated with production of proinflammatory cytokines and endothelial activation, with increased superoxide production and NF-kB regulated synthesis of proinflammatory factors, which were prevented by pharmacological inhibition of TLR4. This raises the possibility that a proinflammatory milieu drives chronic endothelial dysfunction, contributing to CNI-induced hypertension (152).

There is some controversy as to whether the clinical hypertrophic phenotype is related to direct myocardial effects or is in fact due an increase in the incidence of hypertension associated with CsA use. Observations that rats treated with CsA develop hypertension prior to myocardial hypertrophy (4, 101, 153–155) supported the notion that perhaps the clinical hypertrophic phenotype is purely related to CNI-induced hypertension rather than direct myocardial effects. While hypertension may be a contributor to the hypertrophic phenotype observed, multiple animal and cellular models have supported a direct effect of CNI on myocardial remodeling.

mTOR inhibitors

mTOR inhibitors have been associated with a lower risk of hypertension compared to calcineurin inhibitors when used in solid organ transplant recipients (137, 156). The difference between effects of CNI and mTOR inhibitors is likely driven by multiple mechanisms with an overall vasodilatory effect of mTOR inhibitors (157, 158). Sirolimus and everolimus appear to increase nitric oxide production preventing endothelial hyperplasia and dysfunction (133, 134). This promising anti-hypertensive profile has led to the consideration of mTOR inhibitors as a primary therapy for specialized difficult-to-treat populations with hypertension including pulmonary arterial hypertension and primary hyperaldosteronism (138, 139).

Purine synthesis inhibitors

Purine synthesis inhibitors are not associated with hypertension and may in fact have an antihypertensive effect. In comparison to patients treated with CsA after heart transplantation, those treated with azathioprine were less likely to develop hypertension (148). Lower blood pressures have been reported in patients taking MMF for psoriasis and rheumatoid arthritis (145). Possible mechanisms for the favorable hypertensive profile include: lower pro-inflammatory signaling that drives endothelial dysfunction and hyperplasia, decreased circulating levels of endothelin-1, and reduced sodium reabsorption and neuro-hormonal activation leading to hypertension (142–144). Taken together, these data suggest that purine synthesis inhibitors carry a lower risk of systemic hypertension, and may in fact contribute to favorable mechanisms to reduce hypertension in pulmonary hypertension and renal dysfunction-associated hypertension.

Vascular remodeling

In addition to effects on hypertension, immunosuppressive agents may directly contribute to abnormal vascular remodeling to drive cardiovascular adverse events, independent of hypertension or dyslipidemia. Defining this risk and the contributing mechanisms for each drug is important in order to ensure appropriate follow up and identify potential actionable targets to modify the risk profile (Table 5).

Calcineurin inhibitors

CNI, particularly tacrolimus, have been associated with increased risk of allograft vasculopathy (167–169, 191). This notable complication of transplanted hearts represents a major driver of graft dysfunction and has significant implications for quality of life and longevity of heart transplant recipients (163–165). This has been replicated in animal models using both tacrolimus and CsA with adverse remodeling features of vascular stiffness, thickening, inflammation and fibrosis noted in treated animals (159, 160). The mechanisms for these include: decreased fibrinolytic activity in vessel walls, increased oxidative stress in endothelial cells, and possibly increased intracellular calcium in vascular smooth muscle cells (161, 162, 192).

mTOR inhibitors

Both sirolimus and everolimus have been associated with a more favorable vascular profile and their clinical efficacy in reducing the rate of progression of cardiac allograft vasculopathy has led to widespread use in heart transplant recipients (175, 176, 183). In addition to reducing signaling associated with endothelial dysfunction, mTOR inhibitors have been shown to reduce vascular smooth muscle proliferation, intimal hyperplasia, and infiltration by inflammatory cells (170–173, 193, 194). Everolimus, in particular, was shown to reduce pro-inflammatory signaling by decreasing IL-9, VEGF release, and TNFα induced adhesion of endothelial cells (184). These effects have led to wide adoption of everolimus- and sirolimus-eluting stents in the treatment of coronary artery disease (179, 195, 196).

In several trials of kidney transplant patients, a switch from CsA to mTOR inhibitor was associated with stabilization or improvement in parameters of arterial stiffness, including pulse wave velocity (PWV), carotid systolic blood pressure, pulse pressure, and augmentation index (177, 178). One notable exception was a secondary analysis of the ELEVATE trial, where no difference in PWV was found with switch from CsA to everolimus, which was attributed to significant variation in baseline PWV in the study population (75).

In addition to reducing allograft vasculopathy, the anti-vascular proliferation signal conferred by mTOR inhibitors has made the drug class of substantial interest in oncology to suppress tumor neovascularization. Nonetheless, while this anti-proliferation profile offers a substantial benefit, it carries some drawbacks; Namely, both mTOR inhibitor drugs are associated with an increased incidence of lymphedema, which is thought to be driven by inhibition of lymphatic endothelial cell proliferation (197, 198). The incidence of such side effects must be considered in oncologic therapy, where drug dosage is typically higher than that used in transplant immunosuppression (199).

Purine synthesis inhibitors

Purine synthesis inhibitors appear to confer a beneficial vascular remodeling profile. MMF has been associated with reduced atherosclerosis progression and CAV in patients and animal models (119, 142, 185). Animal models point to a signal of decreased vascular oxidative stress and inflammation as the driving mechanism of that benefit (187, 200, 201). Reduced endothelial and smooth muscle proliferation in association with MMF have also been proposed as a possible mechanism, although the evidence is more limited than for mTOR inhibitors (190).

Dyslipidemia

Immunosuppressive medications are associated with dyslipidemia. Each drug class is associated with individual variations in affected lipid particles and more importantly in the conferred risk of atherosclerosis (Table 6).

Calcineurin inhibitors

CsA use is associated with a dose-dependent increase in total cholesterol and low-density lipoprotein (LDL) cholesterol, a decrease in high-density lipoprotein (HDL) cholesterol, and an increase in serum triglycerides (202, 203). These changes are driven by a decrease in lipoprotein lipase and an increase in activity of cholesteryl ester transfer protein (204, 229). Additionally, CsA may reduce expression of the LDL receptor, thereby impairing LDL clearance (230–232). Tacrolimus is associated with a similar, but milder, dyslipidemia profile compared to CsA (130, 209–212). CsA appears to be associated with an increase in oxidized LDL, which confers a higher risk of atherosclerosis, while the data for tacrolimus effect on LDL oxidation are mixed (206–208).

mTOR inhibitors

Sirolimus is a stronger inducer of hyperlipidemia than CNI, associated clinically with an increase in serum LDL and triglyceride levels (70, 218, 233). The mechanism remains unclear, although it may be due to a combination of reduced catabolism, an increase in the free fatty acid pool, increased hepatic production of triglycerides, and secretion of very low density lipoprotein (VLDL) (204, 217). In addition, sirolimus is associated with an increase in serum PCSK9 levels, which acts as a post-transcriptional regulator of LDL receptor expression (234). Clinical data on the risk of dyslipidemia associated with everolimus has been mixed. In clinical studies, everolimus was not associated with an increased risk of dyslipidemia compared to CNI (220, 222, 223, 235–237). However, a meta-analysis comparing mTOR inhibitors to CNI adverse events has noted no difference between sirolimus and everolimus in the incidence of dyslipidemia (238). This suggests that everolimus may contribute to dyslipidemia, but at an intensity that is between CNI and sirolimus.

Interestingly, despite the increase in serum lipids, mTOR inhibitors are associated with an overall lower risk of atherosclerosis (195). Sirolimus reduces oxidized-LDL adhesion and uptake to endothelial cells, and can promote its autophagic degradation (214, 215). Additionally, sirolimus reduces intracellular lipid accumulation in vascular smooth muscle cells, and increases cholesterol efflux via increased expression of the ATP binding cassette protein ABCA1 (216). Similarly everolimus treatment in LDL receptor knockout mice, everolimus increased VLDL/LDL levels but reduced the rate of atherosclerosis. Thus, regardless of dyslipidemia profile, mTOR inhibitors appear to result in a net reduction in the rate of atherosclerosis, which may explain the overall clinical benefit observed.

Purine synthesis inhibitors

Both MMF and azathioprine appear to have a neutral effect on lipids with no significant changes observed in lipid profile in clinical studies (131, 226–228). In vitro studies suggest that MMF increases cholesterol efflux, but another study demonstrated inhibition of lipoprotein lipase activity—the opposing effects may explain the net neutral profile conferred by the drug.

Drug exposure and bioavailability

It is important to note that the bioavailability and exposure levels of the immunosuppression drugs have varied tremendously across clinic and scientific studies in the field. This may explain the differences observed between pre-clinical and clinical studies or even discrepancies between different clinical studies. Part of this variation is not simply investigator mediated, but is driven by variability in clinical practice by geographic area and changes in clinical practice over time. Early CsA trough concentrations in kidney transplant patients ranged 200–500 μg/ml, whereas in Europe, they were typically lower (100–200 μg/ml). Similarly, tacrolimus trough levels ranged 12–20 ηg/ml in the US, and lower in Europe (8–15 ηg/ml). There were also variations in sirolimus and everolimus levels when used in combination with CNI. MMF was previously prescribed at higher doses than is typically used now (2–3 g twice daily to 1 g twice daily) (12, 55, 107, 131).

Conclusions

Immunosuppressive agents exert significant effects on the heart and vasculature. Mechanistic studies point toward immunosuppression drug-specific influences on changes in cell proliferation, mitochondrial function, inflammatory cytokines, and altered calcium handling as potential mediators of these phenotypes. Calcineurin inhibitors promote cardiac hypertrophy, hypertension, dyslipidemia, and vascular remodeling, while mTOR inhibitors have an anti-proliferative effect with attenuation of cardiac hypertrophy and vascular remodeling despite promoting dyslipidemia. Purine synthesis inhibitor are less well studied, but may have a neutral to mildly positive effect on hypertension and vascular remodeling. These phenotypes are associated with significant morbidity in patients taking immunosuppressive medications, carrying increased risks of heart failure, cardiovascular disease, and kidney dysfunction. While preclinical studies have provided invaluable insight into mechanisms of cardiovascular remodeling, the discordance with clinical data, such as in the case of CNI and hypertrophy, highlights the importance of caution in generalizing the results of cell-based and animal models. Further translational research is needed to identify actionable targets to treat associated cardiovascular side effects of immunosuppression drugs.

Funding

NIH T32 HL09427411A1 (AE), NIH K08 HL135343 (KS), and American Heart Association and Enduring Hearts Grant # 924127/Sallam and Hollander/2022 (KS).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1.

  GoldraichLALeitãoSATScolariFLMarcondes-BragaFGBonattoMGMunyalDet al. A comprehensive and contemporary review on immunosuppression therapy for heart transplantation. Curr Pharm Des. (2020) 26:3351–84. 10.2174/1381612826666200603130232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  WallaceBIKenneyBMalaniPNClauwDJNallamothuBKWaljeeAK. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018-2019. JAMA Netw Open. (2021) 4:e214920. 10.1001/jamanetworkopen.2021.4920

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  HarpazRDahlRMDoolingKL. Prevalence of immunosuppression among US adults. JAMA. (2016) 316:2547–8. 10.1001/jama.2016.16477

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  MillerLW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. (2002) 2:807–18. 10.1034/j.1600-6143.2002.20902.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  LevyDGarrisonRJSavageDDKannelWBCastelliWP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. (1990) 322:1561–6. 10.1056/NEJM199005313222203

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  MottramPMMarwickTH. Assessment of diastolic function: what the general cardiologist needs to know. Heart Br Card Soc. (2005) 91:681–95. 10.1136/hrt.2003.029413

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  LuoZShyuKGGualbertoAWalshK. Calcineurin inhibitors and cardiac hypertrophy. Nat Med. (1998) 4:1092–3. 10.1038/2578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  NakataYYoshibayashiMYonemuraTUemotoSInomataYTanakaKet al. Tacrolimus and myocardial hypertrophy. Transplantation. (2000) 69:1960–2. 10.1097/00007890-200005150-00039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  PaolettiE. mTOR inhibition and cardiovascular diseases: cardiac hypertrophy. Transplantation. (2018) 102:S41. 10.1097/TP.0000000000001691

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  SussmanMALimHWGudeNTaigenTOlsonENRobbinsJet al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. (1998) 281:1690–3. 10.1126/science.281.5383.1690

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  MeguroTHongCAsaiKTakagiGMcKinseyTAOlsonENet al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. (1999) 84:735–40. 10.1161/01.RES.84.6.735

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  EtoYYonekuraKSonodaMAraiNSataMSugiuraSet al. Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation. (2000) 101:2134–7. 10.1161/01.CIR.101.18.2134

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  LimHWDe WindtLJSteinbergLTaigenTWittSAKimballTRet al. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation. (2000) 101:2431–7. 10.1161/01.CIR.101.20.2431

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  HillJAKarimiMKutschkeWDavissonRLZimmermanKWangZet al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. (2000) 101:2863–9. 10.1161/01.CIR.101.24.2863

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  DingBPriceRLBorgTKWeinbergEOHalloranPFLorellBH. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res. (1999) 84:729–34. 10.1161/01.RES.84.6.729

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  ZhangWKowalRCRusnakFSikkinkRAOlsonENVictorRG. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. (1999) 84:722–8. 10.1161/01.RES.84.6.722

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  MervaalaEMüllerDNParkJKDechendRSchmidtFFiebelerAet al. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertens Dallas Tex. (2000) 35:360–6. 10.1161/01.HYP.35.1.360

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  LassilaMFinckenbergPPereAKKrogerusLAhonenJVapaataloHet al. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol. (2000) 130:1339–47. 10.1038/sj.bjp.0703422

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  MendeUKagenACohenAAramburuJSchoenFJNeerEJ. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A. (1998) 95:13893–8. 10.1073/pnas.95.23.13893

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  EleftheriadesEGFergusonAGSamarelAM. Cyclosporine A has no direct effect on collagen metabolism by cardiac fibroblasts in vitro. Circulation. (1993) 87:1368–77. 10.1161/01.CIR.87.4.1368

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  ChiJWangLZhangXFuYLiuYChenWet al. Cyclosporin A induces autophagy in cardiac fibroblasts through the NRP-2/WDFY-1 axis. Biochimie. (2018) 148:55–62. 10.1016/j.biochi.2018.02.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  RezzaniRAngosciniPRodellaLBianchiR. Alterations induced by cyclosporine A in myocardial fibers and extracellular matrix in rat. Histol Histopathol. (2002) 17:761–6. 10.14670/HH-17.761

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  KolárFPapousekFMacNaughtonCPelouchVMilerováMKoreckyB. Myocardial fibrosis and right ventricular function of heterotopically transplanted hearts in rats treated with cyclosporin. Mol Cell Biochem. (1996) 163–164:253–60. 10.1007/BF00408666

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  MinnersJvan den BosEJYellonDMSchwalbHOpieLHSackMN. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res. (2000) 47:68–73. 10.1016/S0008-6363(00)00069-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  StovinPGEnglishTA. Effects of cyclosporine on the transplanted human heart. J Heart Transplant. (1987) 6:180–5.

  • Pubmed Abstract
  • Google Scholar

• 26.

  RobertsCASternDLRadioSJ. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. Transplantation. (2002) 74:817–21. 10.1097/00007890-200209270-00015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  EspinoGDenneyJFurlongTFitzsimmonsWNashRA. Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. Bone Marrow Transplant. (2001) 28:1097–103. 10.1038/sj.bmt.1703304

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  KarchSBBillinghamME. Cyclosporine induced myocardial fibrosis: a unique controlled case report. J Heart Transplant. (1985) 4:210–2.

  • Pubmed Abstract
  • Google Scholar

• 29.

  ChoudharyRSastryBKSSubramanyamC. Positive correlations between serum calcineurin activity and left ventricular hypertrophy. Int J Cardiol. (2005) 105:327–31. 10.1016/j.ijcard.2005.04.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  PiotCCroisillePStaatPThibaultHRioufolGMewtonNet al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. (2008) 359:473–81. 10.1056/NEJMoa071142

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  GhaffariSKazemiBTolueyMSepehrvandN. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. Cardiovasc Ther. (2013) 31:e34–39. 10.1111/1755-5922.12010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  CungTTMorelOCaylaGRioufolGGarcia-DoradoDAngoulvantDet al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. (2015) 373:1021–31. 10.1056/NEJMoa1505489

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33.

  OttaniFLatiniRStaszewskyLLaVLLocuratoloNSicuroMet al. Cyclosporine A in reperfused myocardial infarction. J Am Coll Cardiol. (2016) 67:365–74. 10.1016/j.jacc.2015.10.081

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  Chen -ScarabelliCarolScarabelliTM. Cyclosporine a prior to primary PCI in STEMI patients. J Am Coll Cardiol. (2016) 67:375–8. 10.1016/j.jacc.2015.11.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  SakataYMasuyamaTYamamotoKNishikawaNYamamotoHKondoHet al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. (2000) 102:2269–75. 10.1161/01.CIR.102.18.2269

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  ShimoyamaMHayashiDZouYTakimotoEMizukamiMMonzenKet al. [Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension]. J Cardiol. (2001) 37:114–8.

  • Google Scholar

• 37.

  FatkinDMcConnellBKMuddJOSemsarianCMoskowitzIGSchoenFJet al. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest. (2000) 106:1351–9. 10.1172/JCI11093

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38.

  KanazawaKIwai-TakanoMKimuraSOhiraT. Blood concentration of tacrolimus and age predict tacrolimus-induced left ventricular dysfunction after bone marrow transplantation in adults. J Med Ultrason. (2001) 47:97–105. 10.1007/s10396-019-00990-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  AtkisonPJoubertGBarronAGrantDParadisKSeidmanEet al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet Lond Engl. (1995) 345:894–6. 10.1016/S0140-6736(95)90011-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  ManoANakataniTYahataYKatoTHashimotoSWadaKet al. Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report. Transplant Proc. (2009) 41:3831–4. 10.1016/j.transproceed.2009.05.040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  BoluytMOZhengJSYounesALongXO'NeillLSilvermanHet al. Rapamycin Inhibits α1-Adrenergic Receptor–Stimulated Cardiac Myocyte Hypertrophy but Not Activation of Hypertrophy-Associated Genes. Circ Res. (1997) 81:176–86. 10.1161/01.RES.81.2.176

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  GaoXMWongGWangBKiriazisHMooreXLSuYDet al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. (2006) 24:1663–70. 10.1097/01.hjh.0000239304.01496.83

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43.

  GuJHuWSongZPChenYGZhangDDWangCQ. Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway. Front Physiol [Internet]. (2016). Available online at: https://www.frontiersin.org/article/10.3389/fphys.2016.0010410.3389/fphys.2016.00104 (accessed April 28, 2022).

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  YuSYLiuLLiPLiJ. Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg. (2013) 61:223–8. 10.1055/s-0032-1311548

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45.

  ReifsnyderPCRyzhovSFlurkeyKAnunciado-KozaRPMillsIHarrisonDEet al. Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Leprdb mice. Ann N Y Acad Sci. (2018) 1418:106–17. 10.1111/nyas.13557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46.

  LuckCDeMarcoVGMahmoodAGaviniMPPulakatL. Differential Regulation of Cardiac Function and Intracardiac Cytokines by Rapamycin in Healthy and Diabetic Rats. Oxid Med Cell Longev. (2017) 2017:5724046. 10.1155/2017/5724046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47.

  RaichlinEChandrasekaranKKremersWKFrantzRPClavellALPereiraNLet al. Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. Transplantation. (2008) 86:1395–400. 10.1097/TP.0b013e318189049a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48.

  AlnsasraHAslehROhJKMaleszewskiJJLermanAToyaTet al. Impact of sirolimus as a primary immunosuppressant on myocardial fibrosis and diastolic function following heart transplantation. J Am Heart Assoc. (2021) 10:e018186. 10.1161/JAHA.120.018186

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  KushwahaSSRaichlinESheininYKremersWKChandrasekaranKBrunnGJet al. Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J. (2008) 29:2742–50. 10.1093/eurheartj/ehn407

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50.

  AnthonyCImranMPouliopoulosJEmmanuelSIliffJWMoffatKJet al. Everolimus for the prevention of calcineurin-inhibitor-induced left ventricular hypertrophy after heart transplantation (RADTAC Study). JACC Heart Fail. (2021) 9:301–13. 10.1016/j.jchf.2021.01.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51.

  ImamuraTKinugawaKNittaDKinoshitaONawataKOnoM. Everolimus attenuates myocardial hypertrophy and improves diastolic function in heart transplant recipients. Int Heart J. (2016) 57:204–10. 10.1536/ihj.15-320

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  KrishnanATeixeira-PintoAChanDChakeraADograGBoudvilleNet al. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: a randomized controlled trial. Clin Transplant. (2017) 31:10. 10.1111/ctr.13043

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  MurbraechKHoldaasHMasseyRUndsetLHAakhusS. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: an echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation. (2014) 97:184–8. 10.1097/TP.0b013e3182a92728

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54.

  MurbraechKMasseyRUndsetLHMidtvedtKHoldaasHAakhusS. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients–a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clin Transplant. (2015) 29:678–84. 10.1111/ctr.12565

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55.

  de FijterJWHoldaasHØyenOSandersJSSundarSBemelmanFJet al. Early conversion from Calcineurin inhibitor- to Everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. (2017) 17:1853–67. 10.1111/ajt.14186

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56.

  UchinakaAYonedaMYamadaYMuroharaTNagataK. Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome. Pharmacol Res Perspect. (2017) 5:4. 10.1002/prp2.331

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57.

  LiTYuJChenRWuJFeiJBoQet al. Mycophenolate mofetil attenuates myocardial ischemia-reperfusion injury via regulation of the TLR4/NF-κB signaling pathway. Pharm. (2014) 69:850–5. 10.1691/ph.2014.4598

  • CrossRef
  • Google Scholar

• 58.

  KamiyoshiYTakahashiMYokosekiOYazakiYHiroseSIMorimotoHet al. Mycophenolate mofetil prevents the development of experimental autoimmune myocarditis. J Mol Cell Cardiol. (2005) 39:467–77. 10.1016/j.yjmcc.2005.04.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59.

  MolkentinJD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. (2000) 87:731–8. 10.1161/01.RES.87.9.731

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60.

  ZhuWZouYShiojimaIKudohSAikawaRHayashiDet al. Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J Biol Chem. (2000) 275:15239–45. 10.1074/jbc.275.20.15239

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61.

  ZhangW. Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. Cardiovasc Res. (2002) 53:294–303. 10.1016/S0008-6363(01)00451-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62.

  TaigenTDe WindtLJLimHWMolkentinJD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. (2000) 97:1196–201. 10.1073/pnas.97.3.1196

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63.

  PanBLiJParajuliNTianZWuPLewnoMTet al. The calcineurin-TFEB-p62 pathway mediates the activation of cardiac macroautophagy by proteasomal malfunction. Circ Res. (2020) 127:502–18. 10.1161/CIRCRESAHA.119.316007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64.

  NaylerWGGuXHCasleyDJPanagiotopoulosSLiuJMottramPL. Cyclosporine increases endothelin-1 binding site density in cardiac cell membranes. Biochem Biophys Res Commun. (1989) 163:1270–4. 10.1016/0006-291X(89)91115-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65.

  SallamKThomasDGaddamSLopezNBeckABeachLet al. Modeling effects of immunosuppressive drugs on human hearts using induced pluripotent stem cell-derived cardiac organoids and single-cell RNA sequencing. Circulation. (2022) 145:1367–9. 10.1161/CIRCULATIONAHA.121.054317

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66.

  National Heart, Lung, and Blood Institute (NHLBI). Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene Mutations [Internet]. clinicaltrials. (2008). Available online at: https://clinicaltrials.gov/ct2/show/NCT00001965 (accessed May 16, 2022).

  • Google Scholar

• 67.

  KlawitterJNashanBChristiansU. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. (2015) 14:1055–70. 10.1517/14740338.2015.1040388

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68.

  MabasaVHEnsomMHH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit. (2005) 27:666–76. 10.1097/01.ftd.0000175911.70172.2e

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69.

  StentonSBPartoviNEnsomMHH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. (2005) 44:769–86. 10.2165/00003088-200544080-00001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70.

  KahanBDPodbielskiJNapoliKLKatzSMMeier-KriescheHUVan BurenCT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. (1998) 66:1040–6. 10.1097/00007890-199810270-00013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71.

  HallerSTYanYDrummondCAXieJTianJKennedyDJet al. Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling. J Am Heart Assoc. (2016) 5:e004106. 10.1161/JAHA.116.004106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72.

  BussSJMuenzSRiffelJHMalekarPHagenmuellerMWeissCSet al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol. (2009) 54:2435–46. 10.1016/j.jacc.2009.08.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73.

  KlingenbergRStähliBEHegDDenegriAMankaRKaposIet al. Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS)—A phase II, randomized, double-blind, multi-center, placebo-controlled trial. Am Heart J. (2022) 247:33–41. 10.1016/j.ahj.2022.01.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74.

  PascualJ. Everolimus in clinical practice—renal transplantation. Nephrol Dial Transplant. (2006) 21:iii18–23. 10.1093/ndt/gfl300

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75.

  HoldaasHde FijterJWCruzadoJMMassariPNashanBKanellisJet al. Cardiovascular parameters to 2 years after kidney transplantation following early switch to Everolimus without Calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study. Transplantation. (2017) 101:2612–20. 10.1097/TP.0000000000001739

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76.

  PipeleersLAbramowiczDBroedersNLemoineAPeetersPVan LaeckeSet al. 5-Year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients. Transpl Int. (2021) 34:313–26. 10.1111/tri.13798

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77.

  van DijkMvan RoonAMSaidMYBemelmanFJHoman van der HeideJJde FijterHWet al. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial. Transpl Int Off J Eur Soc Organ Transplant. (2018) 31:1380–90. 10.1111/tri.13322

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78.

  JenningsDLTaberDJ. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother. (2008) 42:116–20. 10.1345/aph.1K471

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79.

  GustafssonABGottliebRA. Heart mitochondria: gates of life and death. Cardiovasc Res. (2008) 77:334–43. 10.1093/cvr/cvm005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80.

  YaranaCSripetchwandeeJSanitJChattipakornSChattipakornN. Calcium-induced cardiac mitochondrial dysfunction is predominantly mediated by cyclosporine A-dependent mitochondrial permeability transition pore. Arch Med Res. (2012) 43:333–8. 10.1016/j.arcmed.2012.06.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81.

  RajeshKGSasaguriSRyokoSMaedaH. Mitochondrial permeability transition-pore inhibition enhances functional recovery after long-time hypothermic heart preservation. Transplantation. (2003) 76:1314–20. 10.1097/01.TP.0000085660.93090.79

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82.

  XieJRYuLN. Cardioprotective effects of cyclosporine A in an in vivo model of myocardial ischemia and reperfusion. Acta Anaesthesiol Scand. (2007) 51:909–13. 10.1111/j.1399-6576.2007.01342.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83.

  GriffithsEJHalestrapAP. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol. (1993) 25:1461–9. 10.1006/jmcc.1993.1162

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84.

  MottJLZhangDFreemanJCMikolajczakPChangSWZassenhausHP. Cardiac disease due to random mitochondrial DNA mutations is prevented by cyclosporin A. Biochem Biophys Res Commun. (2004) 319:1210–5. 10.1016/j.bbrc.2004.05.104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85.

  NathanMFriehsIChoiYHCowanDBCao-DanhHMcGowanFXet al. Cyclosporin a but not FK-506 protects against dopamine-induced apoptosis in the stunned heart. Ann Thorac Surg. (2005) 79:1620–6. 10.1016/j.athoracsur.2004.10.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86.

  GaoLHicksMVillanuevaJEDoyleAChewHCQuiMRet al. Cyclosporine A as a cardioprotective agent during donor heart retrieval, storage, or transportation: benefits and limitations. Transplantation. (2019) 103:1140–51. 10.1097/TP.0000000000002629

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87.

  HiemstraJAGutiérrez-AguilarMMarshallKDMcCommisKSZgodaPJCruz-RiveraNet al. A new twist on an old idea part 2: cyclosporine preserves normal mitochondrial but not cardiomyocyte function in mini-swine with compensated heart failure. Physiol Rep. (2014) 2:e12050. 10.14814/phy2.12050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88.

  MarechalXMontaigneDMarciniakCMarchettiPHassounSMBeauvillainJCet al. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clin Sci. (2011) 121:405–13. 10.1042/CS20110069

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89.

  JoshiMSJulianMWHuffJEBauerJAXiaYCrouserED. Calcineurin regulates myocardial function during acute endotoxemia. Am J Respir Crit Care Med. (2006) 173:999–1007. 10.1164/rccm.200411-1507OC

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90.

  NishinakaYSugiyamaSYokotaMSaitoHOzawaT. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. J Cardiovasc Pharmacol. (1993) 21:448–54. 10.1097/00005344-199303000-00015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91.

  SharpWWFangYHHanMZhangHJHongZBanathyAet al. Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. FASEB J Off Publ Fed Am Soc Exp Biol. (2014) 28:316–26. 10.1096/fj.12-226225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92.

  AlbawardiAAlmarzooqiSSaraswathiammaDAbdul-KaderHMSouidAKAlfazariAS. The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration. Int J Physiol Pathophysiol Pharmacol. (2015) 7:54–60.

  • Pubmed Abstract
  • Google Scholar

• 93.

  KhanSSalloumFDasAXiLWVetrovecGCukrejaR. Rapamycin confers preconditioning-like protection against ischemia–reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol. (2006) 41:256–64. 10.1016/j.yjmcc.2006.04.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94.

  JohnsonNKhanAVirjiSWardJMCromptonM. Import and processing of heart mitochondrial cyclophilin D. Eur J Biochem. (1999) 263:353–9. 10.1046/j.1432-1327.1999.00490.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95.

  HausenloyDJBoston-GriffithsEAYellonDM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol. (2012) 165:1235–45. 10.1111/j.1476-5381.2011.01700.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96.

  TennantDADuránRVGottliebE. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. (2010) 10:267–77. 10.1038/nrc2817

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97.

  ZhuJHuaXLiDZhangJXiaQ. Rapamycin attenuates mouse liver ischemia and reperfusion injury by inhibiting endoplasmic reticulum stress. Transplant Proc. (2015) 47:1646–52. 10.1016/j.transproceed.2015.05.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98.

  KlawitterJGottschalkSHainzCLeibfritzDChristiansUSerkovaNJ. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. (2010) 23:608–19. 10.1021/tx900351q

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99.

  SerkovaNChristiansU. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Investig Drugs Lond Engl. (2003) 4:1287–96.

  • Pubmed Abstract
  • Google Scholar

• 100.

  SerkovaNJacobsenWNiemannCULittLBenetLZLeibfritzDet al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. (2001) 133:875–85. 10.1038/sj.bjp.0704142

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101.

  TavaresPReisFRibeiroCAFTeixeiraF. Cardiovascular effects of cyclosporin treatment in an experimental model. Rev Port Cardiol Orgao Of Soc Port Cardiol Port J Cardiol Off J Port Soc Cardiol. (2002) 21:141–55.

  • Pubmed Abstract
  • Google Scholar

• 102.

  BiaryNXieCKauffmanJAkarFG. Biophysical properties and functional consequences of reactive oxygen species (ROS)-induced ROS release in intact myocardium. J Physiol. (2011) 589:5167–79. 10.1113/jphysiol.2011.214239

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103.

  Oropeza-AlmazánYBlatterLA. Mitochondrial calcium uniporter complex activation protects against calcium alternans in atrial myocytes. Am J Physiol Heart Circ Physiol. (2020) 319:H873–81. 10.1152/ajpheart.00375.2020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104.

  HuangYLuCYYanWGaoLChenQZhangYJ. [Influence of cyclosporine A on atrial L-type calcium channel alpha1c subunit in a canine model of atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi. (2009) 37:112–4.

  • Google Scholar

• 105.

  SchreinerKDKelemenKZeheleinJBeckerRSengesJCBauerAet al. Biventricular hypertrophy in dogs with chronic AV block: effects of cyclosporin A on morphology and electrophysiology. Am J Physiol Heart Circ Physiol. (2004) 287:H2891–2898. 10.1152/ajpheart.01051.2003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106.

  GordanRFefelovaNGwathmeyJKXieLH. Iron overload, oxidative stress and calcium mishandling in cardiomyocytes: role of the mitochondrial permeability transition pore. Antioxidants. (2020) 9:758. 10.3390/antiox9080758

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107.

  KoWJLinFLWangSSChuSH. Hypomagnesia and arrhythmia corrected by replacing cyclosporine with FK506 in a heart transplant recipient. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. (1997) 16:980–2.

  • Pubmed Abstract
  • Google Scholar

• 108.

  MayerADDmitrewskiJSquiffletJPBesseTGrabenseeBKleinBet al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. (1997) 64:436–43. 10.1097/00007890-199708150-00012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109.

  MinematsuTOhtaniHSatoHIgaT. Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci. (1999) 65:PL197–202. 10.1016/S0024-3205(99)00396-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110.

  MinematsuTOhtaniHYamadaYSawadaYSatoHIgaT. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. J Pharmacokinet Pharmacodyn. (2001) 28:533–54.

  • Pubmed Abstract
  • Google Scholar

• 111.

  McCallELiLSatohHShannonTRBlatterLABersDM. Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. Circ Res. (1996) 79:1110–21. 10.1161/01.RES.79.6.1110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112.

  DuBellWHWrightPALedererWJRogersTB. Effect of the immunosupressant FK506 on excitation—contraction coupling and outward K+ currents in rat ventricular myocytes. J Physiol. (1997) 501:509–16. 10.1111/j.1469-7793.1997.509bm.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113.

  BellWHGaaST. Lederer WJ, Rogers TB. Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle. Am J Physiol. (1998) 275:H2041–2052. 10.1152/ajpheart.1998.275.6.H2041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114.

  KatanosakaYIwataYKobayashiYShibasakiFWakabayashiSShigekawaM. Calcineurin inhibits Na+/Ca2+ exchange in phenylephrine-treated hypertrophic cardiomyocytes. J Biol Chem. (2005) 280:5764–72. 10.1074/jbc.M410240200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115.

  LiXBilaliAQiaoRPaerhatiTYangY. Association of the PPARγ/PI3K/Akt pathway with the cardioprotective effects of tacrolimus in myocardial ischemic/reperfusion injury. Mol Med Rep. (2018) 17:6759–67.

  • Pubmed Abstract
  • Google Scholar

• 116.

  HodakSPMoubarakJBRodriguezIGelfandMCAlijaniMRTracyCMet al. prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation. (1998) 66:535–7. 10.1097/00007890-199808270-00021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117.

  KimBRShinHSJungYSRimH. A case of tacrolimus-induced supraventricular arrhythmia after kidney transplantation. Sáo Paulo Med J Rev Paul Med. (2013) 131:205–7. 10.1590/1516-3180.2013.1313472

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118.

  NishimuraMKimKUchiyamaAFujinoYNishimuraSTaenakaNet al. Tacrolimus-induced life-threatening arrhythmia in a pediatric liver-transplant patient. Intensive Care Med. (2002) 28:1683–4. 10.1007/s00134-002-1479-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119.

  EisenHJKobashigawaJKeoghABourgeRRenlundDMentzerRet al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil vs. azathioprine in cardiac transplant recipients. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. (2005) 24:517–25. 10.1016/j.healun.2005.02.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120.

  CassinottiAMassariAFerraraEGrecoSBosaniMArdizzoneSet al. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol. (2007) 63:875–8. 10.1007/s00228-007-0328-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121.

  RiccioniGBucciarelliVDi IlioEScottiLAcetoAD'OrazioNet al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature. Int J Immunopathol Pharmacol. (2011) 24:247–9. 10.1177/039463201102400131

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122.

  DoddHJTatnallFMSarkanyI. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J Clin Res Ed. (1985) 291:706. 10.1136/bmj.291.6497.706

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123.

  MurphyGFultonRAKeeganDJ. Fast atrial fibrillation induced by azathioprine. Br Med J Clin Res Ed. (1985) 291:1049–1049. 10.1136/bmj.291.6501.1049-a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124.

  SaygiliERanaORGünzelCRackauskasGSaygiliENoor-EbadFet al. Rate and irregularity of electrical activation during atrial fibrillation affect myocardial NGF expression via different signalling routes. Cell Signal. (2012) 24:99–105. 10.1016/j.cellsig.2011.08.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125.

  SommererCSuwelackBDragunDSchenkerPHauserIAWitzkeOet al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. (2019) 96:231–44. 10.1016/j.kint.2019.01.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126.

  U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. (1994) 331:1110–5. 10.1056/NEJM199410273311702

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127.

  HoškováLMálekIKautznerJHonsováEvan DokkumRPEHuskováZet al. Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin–angiotensin system. Hypertens Res. (2014) 37:724–32. 10.1038/hr.2014.79

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128.

  GrześkEMalinowskiBWicińskiMSzadujkis-SzadurskaKSinjabTAManysiakSet al. Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells. Pharmacol Rep PR. (2016) 68:201–5. 10.1016/j.pharep.2015.08.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129.

  TekesESoydanGTuncerM. The role of endothelin in FK506-induced vascular reactivity changes in rat perfused kidney. Eur J Pharmacol. (2005) 517:92–6. 10.1016/j.ejphar.2005.05.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130.

  TaylorDOBarrMLRadovancevicBRenlundDGMentzerRMSmartFWet al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. (1999) 18:336–45. 10.1016/S1053-2498(98)00060-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131.

  StegallMDWachsMEEversonGSteinbergTBilirBShresthaRet al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation. (1997) 64:1755–60. 10.1097/00007890-199712270-00023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132.

  CanzanelloVJSchwartzLTalerSJTextorSCWiesnerRHPoraykoMKet al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transplant Surg Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. (1997) 3:1–9. 10.1002/lt.500030101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133.

  Temiz-ResitogluMGudenDSSenolSPVezirOSucuNKibarDet al. Pharmacological inhibition of mammalian target of rapamycin attenuates deoxycorticosterone acetate salt–induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation, and cardiovascular hypertrophy in male rats. J Cardiovasc Pharmacol. (2022) 79:355–67. 10.1097/FJC.0000000000001187

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134.

  KimJAJangHJMartinez-LemusLASowersJR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab. (2012) 302:E201–208. 10.1152/ajpendo.00497.2011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135.

  HeYZuoCJiaDBaiPKongDChenDet al. Loss of DP1 aggravates vascular remodeling in pulmonary arterial hypertension via mTORC1 signaling. Am J Respir Crit Care Med. (2020) 201:1263–76. 10.1164/rccm.201911-2137OC

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136.

  TrinhBBurkardT. The mTOR-inhibitor everolimus reduces hypervolemia in patients with primary aldosteronism. Minerva Endocrinol. (2021) 20:1. 10.23736/S2724-6507.21.03382-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137.

  AndreassenAKBrochKEiskjærHKarasonKGudeEMølbakDet al. Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial. Transplantation. (2019) 103:781–8. 10.1097/TP.0000000000002445

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138.

  SeyfarthHJHammerschmidtSHalankMNeuhausPWirtzHR. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. Pulm Circ. (2013) 3:632–8. 10.1086/674311

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139.

  BendtsenMAFGrimmDBauerJWehlandMWisePMagnussonNEet al. Hypertension Caused by Lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. (2017) 18:1736. 10.3390/ijms18081736

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140.

  LewisMJD'CruzD. Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus. Lupus. (2005) 14 Suppl1:s17–26. 10.1177/096120330501400105

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141.

  TaylorEBRyanMJ. Immunosuppression with mycophenolate mofetil attenuates hypertension in an experimental model of autoimmune disease. J Am Heart Assoc. (2017) 6:e005394. 10.1161/JAHA.116.005394

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142.

  BravoYQuirozYFerrebuzAVaziriNDRodríguez-IturbeB. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol. (2007) 293:F616–623. 10.1152/ajprenal.00507.2006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143.

  MoesADSeversDVerdonkKvan der LubbeNZietseRDanserAHJet al. Mycophenolate mofetil attenuates DOCA-salt hypertension: effects on vascular tone. Front Physiol. (2018) 9:578. 10.3389/fphys.2018.00578

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144.

  QuirozYPonsHGordonKLRincónJChávezMParraGet al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol. (2001) 281:F38–47. 10.1152/ajprenal.2001.281.1.F38

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145.

  HerreraJFerrebuzAMacGregorEGRodriguez-IturbeB. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol JASN. (2006) 17:S218–225. 10.1681/ASN.2006080918

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146.

  TinsleyJHChiassonVLSouthSMahajanAMitchellBM. Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension. Am J Hypertens. (2009) 22:1107–14. 10.1038/ajh.2009.125

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147.

  BotrosLSzulcekRJansenSMAKurakulaKGoumansMJTHvan KuilenburgABPet al. The effects of mercaptopurine on pulmonary vascular resistance and BMPR2 expression in pulmonary arterial hypertension. Am J Respir Crit Care Med. (2020) 202:296–9. 10.1164/rccm.202003-0473LE

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148.

  ThompsonMEShapiroAPJohnsenAMItzkoffJMHardestyRLGriffithBPet al. The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. Int J Cardiol. (1986) 11:219–29. 10.1016/0167-5273(86)90181-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149.

  VenturaHOMehraMRStapletonDDSmartFW. Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am. (1997) 81:1347–57. 10.1016/S0025-7125(05)70587-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150.

  TextorSCTalerSJCanzanelloVJSchwartzLAugustineJE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. (2000) 6:521–30. 10.1053/jlts.2000.9737

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151.

  TangQZhengYMSongTReyes-GarcíaJWangCWangYX. Inhibition of big-conductance Ca2+-activated K+ channels in cerebral artery (vascular) smooth muscle cells is a major novel mechanism for tacrolimus-induced hypertension. Pflugers Arch. (2021) 473:53–66. 10.1007/s00424-020-02470-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152.

  Rodrigues-DiezRGonzález-GuerreroCOcaña-SalcedaCRodrigues-DiezRREgidoJOrtizAet al. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. Sci Rep. (2016) 6:27915. 10.1038/srep27915

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153.

  PorterGABennettWMShepsSG. Cyclosporine-associated hypertension. National High Blood Pressure Education Program Arch Intern Med. (1990) 150:280–3. 10.1001/archinte.150.2.280

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154.

  BlumAAravotD. Heart transplantation–an update. Clin Cardiol. (1996) 19:930–8. 10.1002/clc.4960191206

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155.

  MillerLWSchlantRCKobashigawaJKuboSRenlundDG. 24th Bethesda conference: Cardiac transplantation. Task Force 5: Complications J Am Coll Cardiol. (1993) 22:41–54. 10.1016/0735-1097(93)90814-H

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156.

  OberbauerRKreisHJohnsonRWGMotaAClaessonKRuizJCet al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. (2003) 76:364–70. 10.1097/01.TP.0000074360.62032.39

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157.

  SessaAEspositoAGilibertiAIavicoliGCostaCBergalloMet al. Immunosuppressive Agents and Metabolic Factors of Cardiovascular Risk in Renal Transplant Recipients. Transplant Proc. (2009) 41:1178–82. 10.1016/j.transproceed.2009.02.045

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158.

  BootsJMMChristiaansMHLvan HooffJP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients. Drugs. (2004) 64:2047–73. 10.2165/00003495-200464180-00004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159.

  MennanderATiisalaSPaavonenTHalttunenJHäyryP. Chronic rejection of rat aortic allograft. II Administration of cyclosporin induces accelerated allograft arteriosclerosis. Transpl Int Off J Eur Soc Organ Transplant. (1991) 4:173–9. 10.1007/BF00335340

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160.

  MennanderAPaavonenTHäyryP. Cyclosporine-induced endothelialitis and accelerated arteriosclerosis in chronic allograft rejection. Transplant Proc. (1992) 24:341.

  • Pubmed Abstract
  • Google Scholar

• 161.

  DiederichDSkopecJDiederichADaiFX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertens Dallas Tex. (1994) 23:957–61. 10.1161/01.HYP.23.6.957

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162.

  Redondo-HorcajoMRomeroNMartínez-AcedoPMartínez-RuizAQuijanoCLourençoCFet al. Cyclosporine A-induced nitration of tyrosine 34 MnSOD in endothelial cells: role of mitochondrial superoxide. Cardiovasc Res. (2010) 87:356–65. 10.1093/cvr/cvq028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163.

  GaoSZSchroederJSAldermanELHuntSAValantineHAWiederholdVet al. Prevalence of accelerated coronary artery disease in heart transplant survivors. comparison of cyclosporine and azathioprine regimens. Circulation. (1989) 80:III100–105.

  • Pubmed Abstract
  • Google Scholar

• 164.

  MehraMRVenturaHOChambersRBRamireddyKSmartFWStapletonDD. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. (1997) 16:743–51.

  • Pubmed Abstract
  • Google Scholar

• 165.

  GambaAMamprinFFiocchiRSenniMTroiseGFerrazziPet al. The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. Clin Cardiol. (1997) 20:767–72. 10.1002/clc.4960200911

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166.

  De LimaJJXueHCoburnLAndohTFMcCarronDABennettWMet al. Effects of FK506 in rat and human resistance arteries. Kidney Int. (1999) 55:1518–27. 10.1046/j.1523-1755.1999.00366.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167.

  KlaussVKönigASpesCMeiserBRieberJSiebertUet al. Cyclosporine vs. tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol. (2000) 85:266–9. 10.1016/S0002-9149(99)00631-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168.

  ReichartBMeiserBViganòMRinaldiMMartinelliLYacoubMet al. European multicenter tacrolimus (FK506) Heart Pilot Study: one-year results–European tacrolimus multicenter heart study group. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. (1998) 17:775–81.

  • Pubmed Abstract
  • Google Scholar

• 169.

  KoglinJMuschollMPetrakopoulouPGroetznerJWeisMMeiserBet al. Tacrolimus excels cyclosporine a in prevention of cardiac allograft vasculopathy—a prospective IVUS, angiography and doppler study. J Heart Lung Transplant. (2002) 21:68. 10.1016/S1053-2498(01)00471-5

  • CrossRef
  • Google Scholar

• 170.

  ChengCTempelDOostlanderAHeldermanFGijsenFWentzelJet al. Rapamycin modulates the eNOS vs. shear stress relationship. Cardiovasc Res. (2008) 78:123–9. 10.1093/cvr/cvm103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171.

  PhamSMShearsLLKawaharadaNLiSVenkataramananRSehgalS. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. Transplant Proc. (1998) 30:953–4. 10.1016/S0041-1345(98)00107-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172.

  PoonMMarxSOGalloRBadimonJJTaubmanMBMarksAR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. (1996) 98:2277–83. 10.1172/JCI119038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173.

  MarxSOJayaramanTGoLOMarksAR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. (1995) 76:412–7. 10.1161/01.RES.76.3.412

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174.

  BruemmerDYinFLiuJKiyonoTFleckEVan HerleAJet al. Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells. Biochem Biophys Res Commun. (2003) 303:251–8. 10.1016/S0006-291X(03)00343-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175.

  ManciniDPinneySBurkhoffDLaMancaJItescuSBurkeEet al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. (2003) 108:48–53. 10.1161/01.CIR.0000070421.38604.2B

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176.

  PotenaLFearonWFSydowKHolwegCLuikartHChinCet al. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. Transplantation. (2008) 85:827–33. 10.1097/TP.0b013e318166a3a4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177.

  JoannidèsRMonteilCde LignyBHWesteelPFIacobMThervetEet al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. (2011) 11:2414–22. 10.1111/j.1600-6143.2011.03697.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178.

  SeckingerJSommererCHinkelUPHoffmannOZeierMSchwengerV. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens. (2008) 26:2213–9. 10.1097/HJH.0b013e32830ef940

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179.

  SousaJECostaMAAbizaidAAbizaidASFeresFPintoIMet al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. (2001) 103:192–5. 10.1161/01.CIR.103.2.192

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180.

  BaettaRGranataACanavesiMFerriNArnaboldiLBellostaSet al. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther. (2009) 328:419–25. 10.1124/jpet.108.144147

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181.

  BeutnerFBrendelDTeupserDSassKBaberRMuellerMet al. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice. Atherosclerosis. (2012) 222:337–43. 10.1016/j.atherosclerosis.2012.03.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182.

  MuellerMABeutnerFTeupserDCeglarekUThieryJ. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR–/– mice despite severe hypercholesterolemia. Atherosclerosis. (2008) 198:39–48. 10.1016/j.atherosclerosis.2007.09.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183.

  EisenHJTuzcuEMDorentRKobashigawaJManciniDValantine-von KaepplerHAet al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. (2003) 349:847–58. 10.1056/NEJMoa022171

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184.

  NorumHMMichelsenAELekvaTAroraSOtterdalKOlsenMBet al. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. (2019) 19:1050–60. 10.1111/ajt.15141

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185.

  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil cooperative study group. Lancet Lond Engl. (1995) 345:1321–5. 10.1016/S0140-6736(95)92534-1

  • CrossRef
  • Google Scholar

• 186.

  KobashigawaJMillerLRenlundDMentzerRAldermanEBourgeRet al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators Transplantation. (1998) 66:507–15. 10.1097/00007890-199808270-00016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187.

  KrötzFKellerMDerflingerSSchmidHGloeTBassermannFet al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a rac1-dependent mechanism. Hypertension. (2007) 49:201–8. 10.1161/01.HYP.0000251162.14782.d4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188.

  ChangCZWuSCKwanALLinCLHwangSL. 6-Mercaptopurine reverses experimental vasospasm and alleviates the production of endothelins in NO-independent mechanism-a laboratory study. Acta Neurochir (Wien). (2011) 153:939–49. 10.1007/s00701-010-0865-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189.

  PolsTWHBontaPIPiresNMMOterminIVosMde VriesMRet al. 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e^*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol. (2010) 30:1591–7. 10.1161/ATVBAHA.110.205674

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190.

  WeigelGGriesmacherADeAbreuRAWolnerEMuellerMM. Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. Thromb Res. (1999) 94:87–94. 10.1016/S0049-3848(98)00199-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191.

  ValantineH. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. (2004) 23:S187–193. 10.1016/j.healun.2004.03.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192.

  AtkisonPRJoubertGIGuiraudonCArmstrongRWallWAsfarSet al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation. (1997) 64:773–5. 10.1097/00007890-199709150-00020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193.

  AutieriMV. Allograft-induced proliferation of vascular smooth muscle cells: potential targets for treating transplant vasculopathy. Curr Vasc Pharmacol. 1:1–9. 10.2174/1570161033386772

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194.

  VitielloDNeagoePESiroisMGWhiteM. Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation. Cell Mol Immunol. (2015) 12:40–52. 10.1038/cmi.2014.24

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195.

  MartinetWDe LoofHDe MeyerGRY. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis. (2014) 233:601–7. 10.1016/j.atherosclerosis.2014.01.040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196.

  WesselyR. New drug-eluting stent concepts. Nat Rev Cardiol. (2010) 7:194–203. 10.1038/nrcardio.2010.14

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197.

  KobayashiSKishimotoTKamataSOtsukaMMiyazakiMIshikuraH. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. (2007) 98:726–33. 10.1111/j.1349-7006.2007.00439.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198.

  HuberSBrunsCJSchmidGHermannPCConradCNiessHet al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. (2007) 71:771–7. 10.1038/sj.ki.5002112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199.

  VerheijenRBAtrafiFSchellensJHMBeijnenJHHuitemaADRMathijssenRHJet al. Pharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trial. Clin Pharmacokinet. (2018) 57:637–44. 10.1007/s40262-017-0582-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200.

  AllisonACEuguiEM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc. (1994) 26:3205–10.

  • Pubmed Abstract
  • Google Scholar

• 201.

  VoloshynaITeboulIKasselmanLJSalamaMCarsonsSEDeLeonJet al. Macrophage lipid accumulation in the presence of immunosuppressive drugs mycophenolate mofetil and cyclosporin A. Inflamm Res Off J Eur Histamine Res Soc Al. (2019) 68:787–99. 10.1007/s00011-019-01262-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202.

  KasiskeBLTortoriceKLHeim-DuthoyKLAwniWMRaoKV. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis Off J Natl Kidney Found. (1991) 17:700–7. 10.1016/S0272-6386(12)80355-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203.

  BallantyneCMPodetEJPatschWPHaratiYAppelVGottoAMet al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. (1989) 262:53–6. 10.1001/jama.262.1.53

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204.

  ToryRSachs-BarrableKHillJSWasanKM. Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. Int J Pharm. (2008) 358:219–23. 10.1016/j.ijpharm.2008.03.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205.

  DerflerKHaydeMHeinzGHirschlMMStegerGHauserACet al. Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int. (1991) 40:720–7. 10.1038/ki.1991.266

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206.

  ApanayDCNeylanJFRagabMSSgoutasDS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation. (1994) 58:663–9. 10.1097/00007890-199409000-00005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207.

  CofanFCofanMCamposBGuerraRCampistolJMOppenheimerF. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. Transplant Proc. (2005) 37:3791–3. 10.1016/j.transproceed.2005.10.068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208.

  BaiLGabrielsKWijnandsERouschMDaemenMJAPTervaertJWCet al. Low- but not high-dose FK506 treatment confers atheroprotection due to alternative macrophage activation and unaffected cholesterol levels. Thromb Haemost. (2010) 104:143–50. 10.1160/TH09-07-0502

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209.

  JiangYXieXBPengLKPengFHLanGBWangYet al. Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes. Transplant Proc. (2011) 43:1612–5. 10.1016/j.transproceed.2011.03.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210.

  DeleuzeSGarrigueVDelmasSChongGSwarczICristolJPet al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?Transplant Proc. (2006) 38:2311–3. 10.1016/j.transproceed.2006.06.125

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211.

  SteinmüllerTMGräfKJSchleicherJLederKBechsteinWOMuellerARet al. The effect of FK506 vs. cyclosporine on glucose and lipid metabolism–a randomized trial. Transplantation. (1994) 58:669–74. 10.1097/00007890-199409000-00006

  • CrossRef
  • Google Scholar

• 212.

  AbouljoudMSLevyMFKlintmalmGB. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US multicenter trial. US Multicenter Study Group Transplant Proc. (1995) 27:1121–3.

  • Pubmed Abstract
  • Google Scholar

• 213.

  ClaessonKMayerADSquiffletJPGrabenseeBEiglerFWBehrendMet al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine a patients. Transplant Proc. (1998) 30:1292–4. 10.1016/S0041-1345(98)00246-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214.

  ZhouYDCaoXQLiuZHCaoYJLiuCFZhangYLet al. Rapamycin inhibits oxidized low density lipoprotein uptake in human umbilical vein endothelial cells via mTOR/NF-κB/LOX-1 pathway. PLoS One. (2016) 11:e0146777. 10.1371/journal.pone.0146777

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215.

  ChoiSKKwonYByeonSLeeYH. Stimulation of autophagy improves vascular function in the mesenteric arteries of type 2 diabetic mice. Exp Physiol. (2020) 105:192–200. 10.1113/EP087737

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216.

  MaKLRuanXZPowisSHMoorheadJFVargheseZ. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. (2007) 292:H2721–2728. 10.1152/ajpheart.01174.2006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217.

  AiDChenCHanSGandaAMurphyAJHaeuslerRet al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest. (2012) 122:1262–70. 10.1172/JCI61919

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218.

  BrattströmCWilczekHTydénGBöttigerYSäweJGrothCG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation. (1998) 65:1272–4. 10.1097/00007890-199805150-00023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219.

  TurMDGarrigueVVelaCDupuyAMDescompsBCristolJPet al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc. (2000) 32:2783–4. 10.1016/S0041-1345(00)01884-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220.

  LevyGSchmidliHPunchJTuttle-NewhallEMayerDNeuhausPet al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. (2006) 12:1640–8. 10.1002/lt.20707

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221.

  KasiskeBLde MattosAFlechnerSMGallonLMeier-KriescheHUWeirMRet al. Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients. Am J Transplant. (2008) 8:1384–92. 10.1111/j.1600-6143.2008.02272.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222.

  RosingKFobkerMKannenbergFGuniaSDell'AquilaAMKwiecienRet al. Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Atherosclerosis. (2013) 230:164–70. 10.1016/j.atherosclerosis.2013.07.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223.

  EngelenMAAmlerSWelpHVahlhausCGuniaSSindermannJRet al. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years. Transplantation. (2011) 91:1159–65. 10.1097/TP.0b013e31821774bd

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224.

  SatoSAkamineYKagayaHSaitoMInoueTNumakuraKet al. Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1. Pharmacol Rep PR. (2020) 72:622–30. 10.1007/s43440-020-00090-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225.

  SchreiberTCGreensteinSMKimDYCalderonTMSunSSchechnerRSet al. Effect of Mycophenolate Mofetil on Atherosclerosis in a Rabbit Model: Initial Histologic and Immunohistochemical Analyses 11Supported by Roche, Inc (Nutley, NJ). Transplant Proc. (1998) 30:961–2. 10.1016/S0041-1345(98)00111-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226.

  PerreaDNMoulakakisKGPoulakouMVVlachosISNikiteasNKostakisA. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol. (2008) 40:521–7. 10.1007/s11255-007-9266-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227.

  van den DorpelMAGhanemHRischen-VosJMan in't VeldAJJansenHWeimarW. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int. (1997) 51:1608–12. 10.1038/ki.1997.221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228.

  AkmanBUyarMAfsarBSezerSOzdemirFNHaberalM. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids. Transplant Proc. (2007) 39:135–7. 10.1016/j.transproceed.2006.10.210

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 229.

  de GroenPC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc. (1988) 63:1012–21. 10.1016/S0025-6196(12)64916-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230.

  RayyesOWallmarkAFlorénC. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology. (1996) 24:613–9. 10.1002/hep.510240325

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231.

  López-MirandaJVilellaEPérez-JiménezFEspinoAJiménez-Perepérez JoséAMasanaLet al. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism. (1993) 42:678–83. 10.1016/0026-0495(93)90232-D

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232.

  KockxMKritharidesL. Chapter 25—Cyclosporin A-Induced Dyslipidemia and LDL Receptors. In: PatelVB, editor. The Molecular Nutrition of Fats [Internet]. Academic Pr. (2019). p. 323–33. Available online at: https://www.sciencedirect.com/science/article/pii/B9780128112977000251 (accessed June 18, 2022).

  • Google Scholar

• 233.

  MacDonaldAS. RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. (2001) 71:271–80. 10.1097/00007890-200101270-00019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234.

  SimhaVQinSShahPSmithBHKremersWKKushwahaSet al. Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients. J Cardiovasc Transl Res. (2017) 10:9–15. 10.1007/s12265-016-9719-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235.

  VitkoSTedescoHErisJPascualJWhelchelJMageeJCet al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. (2004) 4:626–35. 10.1111/j.1600-6143.2004.00389.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236.

  HoldaasHPotenaLSalibaF. mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?Transplant Rev. (2015) 29:93–102. 10.1016/j.trre.2014.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237.

  PascualJ. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. Transplantation. (2005) 79:S76–79. 10.1097/01.TP.0000162434.62591.F3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238.

  MurakamiNRiellaLVFunakoshiT. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant. (2014) 14:2317–27. 10.1111/ajt.12852

  • Pubmed Abstract
  • CrossRef
  • Google Scholar